<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147757</url>
  </required_header>
  <id_info>
    <org_study_id>4-2010-0129</org_study_id>
    <nct_id>NCT01147757</nct_id>
  </id_info>
  <brief_title>Effect of Intraoperative Remifentanil Infusion Rate on Postoperative Tolerance and Analgesic Consumption in Pediatric Laparoscopic Ureteroneocystostomy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of intraoperative remifentanil infusion rate on postoperative tolerance and analgesic
      consumption in pediatric laparoscopic ureteroneocystostomy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fentanyl consumption for IV-PCA</measure>
    <time_frame>24 h and 48 h after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>during 48 h after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group S (n = 15): saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil 0.3 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil 0.6 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil 0.9 mcg/kg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>During surgery, 3 different dose of remifentanil or placebo was infused.</description>
    <arm_group_label>saline</arm_group_label>
    <arm_group_label>remifentanil 0.3 mcg/kg/min</arm_group_label>
    <arm_group_label>remifentanil 0.6 mcg/kg/min</arm_group_label>
    <arm_group_label>remifentanil 0.9 mcg/kg/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients (ASA physical status I and II) aged between 1-5 yrs and scheduled
             elective laparoscopic ureteroneocystostomy

        Exclusion Criteria:

          -  cardiovascular, renal, liver disease or growth retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Yeon Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-Yeon Hong</last_name>
    <email>jenyhongg@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Yeon Hong, M.D.</last_name>
      <phone>82-2-2228-2427</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jeong-Yeon Hong</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>pediatric patients (ASA physical status I or II) aged between</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

